BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children

Phase 1

Completed

Conditions: Thrombosis

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939

First Posted Date: 2015-07-14

Last Posted Date: 2019-04-16

Lead Sponsor: Bayer

Target Recruit Count: 47

Registration Number: NCT02497716

Locations: 🇺🇸
Children's Hospital Oakland, Oakland, California, United States
🇺🇸
Riley Hospital For Children, Indianapolis, Indiana, United States
🇺🇸
Carolinas Healthcare System, Charlotte, North Carolina, United States

and more 18 locations

To Investigate the Pharmacological Effects, Drug Blood Levels and Safety of an Intrauterine System Releasing the Study Drug BAY1007626 in Comparison to Mirena and Jaydess in Healthy Young Women Treated for 90 Days to Determine the Drug Dose for Further Development

Phase 2

Terminated

Conditions: Contraception

Interventions: Drug: BAY1007626
Drug: Jaydess
Drug: Mirena

First Posted Date: 2015-07-07

Last Posted Date: 2019-06-04

Lead Sponsor: Bayer

Target Recruit Count: 174

Registration Number: NCT02490774

Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Interferon beta-1b (Betaferon, BAY86-5046)
Device: Betaconnect Autoinjector

First Posted Date: 2015-07-01

Last Posted Date: 2023-07-24

Lead Sponsor: Bayer

Target Recruit Count: 162

Registration Number: NCT02486640

Real-Life Evidence on Stroke Prevention in SPAF

Completed

Conditions: Atrial Fibrillation (Prevention of Stroke)

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Vitamin K antagonists

First Posted Date: 2015-06-30

Last Posted Date: 2015-11-11

Lead Sponsor: Bayer

Target Recruit Count: 8607

Registration Number: NCT02485873

Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BAY94-9343

First Posted Date: 2015-06-30

Last Posted Date: 2018-06-04

Lead Sponsor: Bayer

Target Recruit Count: 12

Registration Number: NCT02485119

Locations: 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵
National Cancer Center Hospital, Tyuo, Japan

Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate

Phase 1

Completed

Conditions: Hemophilia A

Interventions: Drug: BAY81-8973
Drug: Advate

First Posted Date: 2015-06-26

Last Posted Date: 2016-02-17

Lead Sponsor: Bayer

Target Recruit Count: 18

Registration Number: NCT02483208

Prospective, Non-interventional, Multi-center Safety Study of Mirena for Heavy Menstrual Bleeding and Dysmenorrhea

Completed

Conditions: Menorrhagia, Dysmenorrhea

Interventions: Drug: Levonorgestrel IUS (Mirena, BAY86-5028)

First Posted Date: 2015-06-18

Last Posted Date: 2021-01-28

Lead Sponsor: Bayer

Target Recruit Count: 601

Registration Number: NCT02475356

An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres

Completed

Conditions: Stroke
Atrial Fibrillation
Prevention and Control

Interventions: Drug: Direct Oral Anticoagulant (DOAC)

First Posted Date: 2015-06-12

Last Posted Date: 2017-02-16

Lead Sponsor: Bayer

Target Recruit Count: 792

Registration Number: NCT02470767

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Completed

Conditions: Venous Thrombosis
Acute Coronary Syndrome
Pulmonary Embolism
Atrial Fibrillation

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Standard of care drugs

First Posted Date: 2015-06-10

Last Posted Date: 2021-09-27

Lead Sponsor: Bayer

Target Recruit Count: 99999

Registration Number: NCT02468102

Locations: 🇸🇪
Many Locations, Multiple Locations, Sweden

Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids

Phase 2

Completed

Conditions: Leiomyoma

Interventions: Drug: Vilaprisan (BAY1002670
Drug: Vilaprisan (BAY1002670)
Drug: Ulipristal

First Posted Date: 2015-06-09

Last Posted Date: 2016-11-22

Lead Sponsor: Bayer

Target Recruit Count: 120

Registration Number: NCT02465814

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy